search
clinical researchers
Trends
- 1Clinical trial genetic data exposed in academic database breaches●Clinical trial data including genetic and medical history information has been exposed in academic research database bre
Breaches of academic research databases have exposed clinical trial data, including genetic and medical history information, affecting thousands of study participants. Privacy advocates are urging people to use their HIPAA rights to request their medical records and a list of everyone those records were shared with, and to correct errors. The incident has reignited debate over how universities and research institutions safeguard sensitive participant data.
- 2Blood thinners cut atrial fibrillation risk by 69%▼Atrial fibrillation patients saw 69% lower risk with common blood thinners
New findings reported by ScienceDaily indicate that atrial fibrillation patients taking common blood thinners saw a 69% lower risk, presumably of stroke or related complications. The figure is drawing attention among patients and clinicians, as anticoagulant guidelines continue to be debated and researchers look for clearer evidence on who benefits most from long-term blood thinner treatment.
- 3Epigenetic Editing Edges Closer to Clinical Use▼Epigenetic Editing Steps Closer to the Clinic as Bioengineering Tools Mature
Reports say epigenetic editing — altering gene activity without changing DNA sequence — is moving closer to clinical application as the bioengineering tools behind it mature. Unlike CRISPR-style gene cutting, epigenetic approaches aim to switch genes on or off reversibly, and researchers see growing potential for treating disease with fewer permanent risks. The field is watching which tools and trials will translate first.
- 4AI Clinical Monitoring Tool Reported to Cut Trial Costs by Millions▼AI Clinical Monitoring Tool Saves Millions in Trial Costs
An AI-powered clinical monitoring tool is reported to have saved millions of dollars in clinical trial costs, according to coverage in The Scientist. The tool is said to streamline monitoring of trial sites, reducing manual oversight work and associated expenses. The report highlights growing interest in applying artificial intelligence to make drug development faster and cheaper, though detailed figures and trial specifics were not provided.
- 5AI-identified biomarker looks accurate but fails key test▼An AI-identified biomarker can look accurate and still fail its biggest test
A new report warns that a biomarker identified through artificial intelligence can appear accurate in its initial analysis yet still fail when put to its biggest test, typically validation in independent or clinical settings. The finding highlights a growing concern in medical research: AI-driven discoveries may reflect patterns in data rather than real, clinically useful signals, and researchers are being urged to apply stricter validation before trusting such results.
- 6IBA and Penn Medicine Launch Noventra Oncology Joint Venture▼IBA, Penn Medicine Announce Noventra Oncology Alliance Joint Venture
IBA and Penn Medicine have announced the creation of Noventra Oncology Alliance, a joint venture focused on oncology. The partnership combines IBA's technology background with Penn Medicine's clinical and research expertise to develop and advance cancer treatment solutions. Details on funding, leadership and the venture's first programs have not yet been made public.
- 7Eric Deutsch on the Fast-Growing Science Linking Radiation Oncology and Immunology▼Eric Deutsch: The Science Is Expanding Fast at the Interface of Radiation Oncology, Immunology, and Technology
Radiation oncology expert Eric Deutsch says science is expanding rapidly at the intersection of radiation therapy, immunology, and technology, as combined approaches such as radiotherapy paired with immunotherapy gain ground in cancer treatment. His remarks highlight how technological advances and immune-based research are reshaping how clinicians think about radiation's role beyond tumour destruction.